Astrazeneca Stock News

German Health Insurer Reveals ''Alarming'' Underreporting Of Vaccine Side-Effects A large German health insurance provider revealed on Wednesday that Covid-19 vaccine side-effects are vastly underreported, according to Welt . After analyzing data from over 10 million individuals, BKK ProVita board member Andreas Schöfbeck, over a 7.5 month period beginning in early 2021, 216,695 policyholders out of 10.9 million were treated for vaccine side-effects. This compares to 244,576 reports out of 61.4 million reported by the Paul Ehrlich Institute - a German federal agency. Germany has a population of around 83 million people. Schöfbeck called the data an "alarm signal," adding "The numbers determined are significant and urgently need to be checked for plausibility." " The data available to our company gives us reason to believe that there is a very considerable under-recording of suspected cases of vaccination side-effects after they received the [COVID-19] vaccine. " “If these figures are applied to the year as a whole and to” the entire population of Germany, Schöfbeck estimated, then “ probably 2.5-3 million people in Germany been under medical treatment because of vaccination side effects after [COVID-19] vaccination. ” As Jack Phillips of The Epoch Times notes: Schöfbeck concluded that based on their data, “there is a significant underreporting of vaccination side-effects ” in Germany.

OTTAWA — The Canadian government has signed an agreement with pharmaceutical company AstraZeneca to procure 100,000 doses of a COVID-19 antibody therapy that''s still under review by Health Canada.

MISSISSAUGA, ON , Feb. 23, 2022 /CNW/ - AstraZeneca Canada has signed an agreement with the Government of Canada for the supply of 100,000 doses of Evusheld (tixagevimab co-packaged with cilgavimab), its long-acting antibody (LAAB) combination for the prevention (pre-exposure prophylaxis) of COVID-19 in those patient populations who require additional protection. Doses will be delivered in 2022, should Evusheld (the proposed trade name for AZD7442), receive regulatory approval from Health Canada. In November 2021 , AstraZeneca Canada announced it had initiated a rolling review New Drug Submission with Health Canada for the authorization of Evusheld . If granted, Evusheld would be the first LAAB combination to receive Health Canada authorization for COVID-19 prevention. "Thousands of Canadians remain at serious risk for COVID-19 because they are unable to mount an adequate response to a vaccine due to an underlying health condition or medication they take that compromises their immune system," said Kiersten Combs , President of AstraZeneca Canada.

AstraZeneca PLC (NASDAQ:AZN) traded at $60.83 at last check on Wednesday, February 23, made an upward move of 0.03% on its previous day’s price. Looking at the stock we see that its previous close was $60.81 and the beta (5Y monthly) reads 0.19 with the day’s price range being $60.55 – $61.91. The company has … AstraZeneca PLC (NASDAQ: AZN) Is The Among Hot Stock Right Now Read More »

A large study into rare blood clots linked with AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine found between one and three cases per million, and only after the first dose. The analysis sheds fre

BUCHAREST: Romania will donate 1.1 million AstraZeneca COVID-19 vaccines to Pakistan, Bangladesh, Algeria and Libya, the health ministry said on Wednesday. Romania is the European Union''s second-least vaccinated country after Bulgaria, with roughly 42% of the population fully inoculated, reflecting mistrust in state institutions and poor vaccine education. With supplies far outstripping demand for COVID-19 shots, the Bucharest government has sold or donated excess shots before their expiry date. Valeriu Gheorghita, a doctor in charge of coordinating Romania''s vaccination campaign said earlier this month that some 900,000 expired AstraZeneca doses were set to be destroyed. The global project to share COVID-19 vaccines is struggling to place more than 300 million doses, underlining that the problem with vaccinating the world is now more about demand than supply. Short AstraZeneca shelf life complicates Covid vaccine rollout to worlds poorest Romania reported 11,477 new cases of COVID-19 on Wednesday, far off record highs registered at the start of this month at the peak of the Omicron coronavirus variant wave.

A global clinical trial was launched Tuesday to investigate the impact of reduced COVID-19 booster shots, as opposed to full ones, as a way to improve access to vaccines for those parts of the world t

Osagie Ehanire, Minister for Health, has expressed concern that the number of Nigerians who have been fully vaccinated is still very low because the country has been administering double dose vaccines. The minister decried that most persons who have received their first dose are reluctant to take their second dose for various reasons including fear of a repeat of the mild side effects they may have experienced with the first dose. The minister raised this concern during the launch of SCALES 2.0 strategy, which stands for Service delivery, Communication, Accountability, Logistics, Electronic Reporting, and Supportive Supervision to scale up COVID-19 vaccination organised by the National Primary Health Care Development Agency (NPHCDA). Ehanire disclosed that as of 18th February, Nigeria has administered over 20million doses, representing over 18 percent of the 111,176,503 eligible population targeted for COVID-19 vaccination. THE minister, however, assured that the federal government have over 30 million doses of teh Johnson and Johnson vaccine stock, which is a single-dose vaccine and urged Nigerians to show up for vaccination.

Safe stocks tend to perform well no matter what the broader market does. Here are seven defensive companies to research further.

AstraZeneca (AZN) said on Feb. 17 that the European Medicines Agency accepted its application for nirsevimab under an accelerated assessment for the prevention of lower respiratory

It''s the big pharma company that "has the best stuff with the least warts, says T. Rowe Prices Ziad Bakri.

AstraZeneca popped to a three-month high after the company touted a previously unheard-of result for its breast cancer treatment, Enhertu.

Roche Holdings AG (OTC: RHHBY ) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN ), centering around the latter''s newly acquired rare disease drug Ultomiris for a rare blood disorder. Roche''s Chugai Pharmaceutical and AstraZeneca''s Alexion inked a deal to end a lawsuit claiming Alexion unlawfully used Chugai''s patented drug-delivery technology to reduce the dosing frequency for blockbuster Ultomiris, Full story available on Benzinga.com

NEW YORK , Feb. 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XOM, AZN, PXD, CSCO, and TSLA. Full story available on Benzinga.com

AstraZeneca's (AZN) DESTINY-Breast04 is the first-ever phase III study of a HER2-directed therapy to show a statistically significant and clinically meaningful survival benefit in patients with HER2-l